Literature DB >> 14978773

In vitro and in vivo delivery of intact BAC DNA -- comparison of different methods.

C Magin-Lachmann1, G Kotzamanis, L D'Aiuto, H Cooke, C Huxley, E Wagner.   

Abstract

BACKGROUND: The ability to deliver large (>100 kb) fragments of DNA to mammalian cells in vitro and in vivo is becoming increasingly important with the availability of BAC and PAC constructs for gene expression. Here we investigate in vitro and in vivo delivery of BACs up to 157 kb.
METHODS: Different types of polyethylenimine (PEI) and Lipofectamine were used to deliver 150-kb BAC (bacterial artificial chromosome) DNA to mouse and human cell lines in tissue culture and the level of EGFP expression compared. To assess the intactness of the DNA delivered, a BAC carrying oriP/EBNA-1 was used to make stably transfected cell lines. Episomal DNA was then rescued into E. coli followed by analysis on a pulsed-field gel. Three different methods of in vivo delivery were also assessed for delivery of BAC DNA; intravenous injection of DNA/PEI particles, intramuscular injection with electroporation and high-volume injection into the tail vein.
RESULTS: PEI22 (linear polymer form, 22 kDa) was found to be the most efficient method for delivery of 150-kb BAC DNA to both cell lines in tissue culture. However, Lipofectamine 2000 was found to give a higher proportion of intact DNA than PEI22 in stably transformed colonies and almost all the DNA delivered by Lipofectamine 2000 was intact. Intravenous injection of DNA/PEI particles was found to be inefficient for delivery of BAC DNA. Intramuscular injection with electroporation of pure BAC DNA was very efficient and expression was maintained for 105 days. High-volume injection of BAC DNA gave excellent expression in the liver and intact BAC DNA could be rescued 7 days after injection.
CONCLUSIONS: These results demonstrate efficient delivery of intact, large (up to 157 kb) DNA constructs for in vitro gene expression and in vivo gene therapy applications. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978773     DOI: 10.1002/jgm.481

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  18 in total

Review 1.  Nonviral gene delivery: what we know and what is next.

Authors:  Xiang Gao; Keun-Sik Kim; Dexi Liu
Journal:  AAPS J       Date:  2007-03-23       Impact factor: 4.009

2.  Transient expression of proteins by hydrodynamic gene delivery in mice.

Authors:  Daniella Kovacsics; Jayne Raper
Journal:  J Vis Exp       Date:  2014-05-05       Impact factor: 1.355

Review 3.  Hydrodynamic gene delivery and its applications in pharmaceutical research.

Authors:  Barbara Bonamassa; Li Hai; Dexi Liu
Journal:  Pharm Res       Date:  2010-12-30       Impact factor: 4.200

4.  Characterization of a large human transgene following invasin-mediated delivery in a bacterial artificial chromosome.

Authors:  Austin E Gillen; Catherine A Lucas; Pei Ling Haussecker; Steven T Kosak; Ann Harris
Journal:  Chromosoma       Date:  2013-06-09       Impact factor: 4.316

5.  Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.

Authors:  Sara Pérez-Luz; Javier Díaz-Nido
Journal:  J Biomed Biotechnol       Date:  2010-08-24

6.  Comparative genomics reveals a functional thyroid-specific element in the far upstream region of the PAX8 gene.

Authors:  Roberto Nitsch; Valeria Di Dato; Alessandra di Gennaro; Tiziana de Cristofaro; Serena Abbondante; Mario De Felice; Mariastella Zannini; Roberto Di Lauro
Journal:  BMC Genomics       Date:  2010-05-14       Impact factor: 3.969

7.  Long-term physiologically regulated expression of the low-density lipoprotein receptor in vivo using genomic DNA mini-gene constructs.

Authors:  Olivia C Hibbitt; Eileen McNeil; Michele Mp Lufino; Len Seymour; Keith Channon; Richard Wade-Martins
Journal:  Mol Ther       Date:  2009-10-27       Impact factor: 11.454

8.  Stable replication of the EBNA1/OriP-mediated baculovirus vector and its application to anti-HCV gene therapy.

Authors:  Hitoshi Suzuki; Norihiko Matsumoto; Tomoyuki Suzuki; Myint Oo Chang; Hiroshi Takaku
Journal:  Virol J       Date:  2009-10-02       Impact factor: 4.099

9.  Regulated expression of a transgene introduced on an oriP/EBNA-1 PAC shuttle vector into human cells.

Authors:  Hanne A Askautrud; Elisabet Gjernes; Gro L Størvold; Mona M Lindeberg; Jim Thorsen; Hans Prydz; Eirik Frengen
Journal:  BMC Biotechnol       Date:  2009-10-16       Impact factor: 2.563

10.  Identification of an exonic splicing silencer in exon 6A of the human VEGF gene.

Authors:  Rui Wang; Ronald G Crystal; Neil R Hackett
Journal:  BMC Mol Biol       Date:  2009-11-17       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.